IXO is a biotechnology company researching and developing novel immunotherapeutics targeting the innate immune system. Focusing on the initiators of the adaptive immune response, IXO’s products address significant unmet clinical need in areas of high commercial value. Based in the UK, IXO’s products are in late-stage research and preclinical development based on IP derived from both NERC
and the University of Oxford.



Leave a comment

February 19, 2013 · 12:52 am

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s